chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Cough, Inappropriate schedule of product administration, Nasal congestion, Onychoclasis
Clinical narrative: I got my second shot on 13 may; Finger tips hurt; Finger tips to peel; Nails to fall off; Sensitivity to sun; tested positive for COVID-19; Stuffy nose; Coughing a bit; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (Finger tips hurt), SKIN EXFOLIATION (Finger tips to peel), ONYCHOCLASIS (Nails to fall off), PHOTOSENSITIVITY REACTION (Sensitivity to sun) and COVID-19 (tested positive for COVID-19) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037K20A and 003B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concurrent medical conditions included Parkinson's disease. Concomitant products included CARBIDOPA MONOHYDRATE;LEVODOPA, CARBIDOPA, LEVODOPA (CARBIDOPA/LEVODOPA) and RASAGILINE MESYLATE (AZILECT) for Parkinson's disease.   On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Jan-2021, the patient experienced NASAL CONGESTION (Stuffy nose) and COUGH (Coughing a bit). On 27-Jan-2021, the patient experienced COVID-19 (tested positive for COVID-19). On 29-Jan-2021, the patient experienced PAIN IN EXTREMITY (Finger tips hurt), SKIN EXFOLIATION (Finger tips to peel), ONYCHOCLASIS (Nails to fall off) and PHOTOSENSITIVITY REACTION (Sensitivity to sun). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (I got my second shot on 13 may). The patient was treated with DOXYCYCLINE (DOXYCYCLIN [DOXYCYCLINE]) on 28-Jan-2021 at a dose of 1 dosage form. On 12-Feb-2021, PHOTOSENSITIVITY REACTION (Sensitivity to sun) had resolved. At the time of the report, PAIN IN EXTREMITY (Finger tips hurt), SKIN EXFOLIATION (Finger tips to peel), ONYCHOCLASIS (Nails to fall off), COVID-19 (tested positive for COVID-19), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (I got my second shot on 13 may), NASAL CONGESTION (Stuffy nose) and COUGH (Coughing a bit) outcome was unknown.            No treatment information were reported.   This case was linked to MOD21-084040 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: Follow-up was received on 15-Jun-2021 and contains significant information. Patient demographics, address were updated. The outcome date of the event (Photosensitivity) was updated.; Sender's Comments:  MOD21-084040:cross linked id
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Photosensitivity reaction, Skin exfoliation
Clinical narrative: I got my second shot on 13 may; Finger tips hurt; Finger tips to peel; Nails to fall off; Sensitivity to sun; tested positive for COVID-19; Stuffy nose; Coughing a bit; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (Finger tips hurt), SKIN EXFOLIATION (Finger tips to peel), ONYCHOCLASIS (Nails to fall off), PHOTOSENSITIVITY REACTION (Sensitivity to sun) and COVID-19 (tested positive for COVID-19) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037K20A and 003B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concurrent medical conditions included Parkinson's disease. Concomitant products included CARBIDOPA MONOHYDRATE;LEVODOPA, CARBIDOPA, LEVODOPA (CARBIDOPA/LEVODOPA) and RASAGILINE MESYLATE (AZILECT) for Parkinson's disease.   On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Jan-2021, the patient experienced NASAL CONGESTION (Stuffy nose) and COUGH (Coughing a bit). On 27-Jan-2021, the patient experienced COVID-19 (tested positive for COVID-19). On 29-Jan-2021, the patient experienced PAIN IN EXTREMITY (Finger tips hurt), SKIN EXFOLIATION (Finger tips to peel), ONYCHOCLASIS (Nails to fall off) and PHOTOSENSITIVITY REACTION (Sensitivity to sun). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (I got my second shot on 13 may). The patient was treated with DOXYCYCLINE (DOXYCYCLIN [DOXYCYCLINE]) on 28-Jan-2021 at a dose of 1 dosage form. On 12-Feb-2021, PHOTOSENSITIVITY REACTION (Sensitivity to sun) had resolved. At the time of the report, PAIN IN EXTREMITY (Finger tips hurt), SKIN EXFOLIATION (Finger tips to peel), ONYCHOCLASIS (Nails to fall off), COVID-19 (tested positive for COVID-19), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (I got my second shot on 13 may), NASAL CONGESTION (Stuffy nose) and COUGH (Coughing a bit) outcome was unknown.            No treatment information were reported.   This case was linked to MOD21-084040 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: Follow-up was received on 15-Jun-2021 and contains significant information. Patient demographics, address were updated. The outcome date of the event (Photosensitivity) was updated.; Sender's Comments:  MOD21-084040:cross linked id
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Vision blurred
Clinical narrative: Seen blurry; This spontaneous case was reported by a consumer and describes the occurrence of VISION BLURRED (Seen blurry) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reported.  Concomitant products included CALCIUM for Osteoporosis, SIMVASTATIN for an unknown indication.   On 26-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Apr-2021, the patient experienced VISION BLURRED (Seen blurry). On 26-Apr-2021, VISION BLURRED (Seen blurry) had resolved. Not Provided          Action taken with mRNA-1273 in response to the event was not applicable.  Treatment information was not provided.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Vaccination site hypersensitivity, Vaccination site pain
Clinical narrative: Feeling tired; Fatigue; Injection site became sore again; Sensitivity on the injection site again; Exhausted; Headache; The pain in the injection site"; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE HYPERSENSITIVITY (Sensitivity on the injection site again), FATIGUE (Exhausted), HEADACHE (Headache), VACCINATION SITE PAIN (The pain in the injection site") and VACCINATION SITE PAIN (Injection site became sore again) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013AZ119 and 021B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Arthritis (Arthritis on thumb on other arm.).   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Apr-2021, the patient experienced FATIGUE (Exhausted), HEADACHE (Headache) and VACCINATION SITE PAIN (The pain in the injection site"). On 08-Apr-2021, the patient experienced VACCINATION SITE HYPERSENSITIVITY (Sensitivity on the injection site again) and VACCINATION SITE PAIN (Injection site became sore again). On an unknown date, the patient experienced FATIGUE (Feeling tired) and FATIGUE (Fatigue). At the time of the report, VACCINATION SITE HYPERSENSITIVITY (Sensitivity on the injection site again), FATIGUE (Exhausted), HEADACHE (Headache), VACCINATION SITE PAIN (The pain in the injection site"), VACCINATION SITE PAIN (Injection site became sore again), FATIGUE (Feeling tired) and FATIGUE (Fatigue) outcome was unknown.            No concomitant medicines were reported. No treatment information were reported.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Hypersomnia, Nausea, Pain in extremity
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of pain in extremity (sore arm), hypersomnia (slept a lot), fatigue (felt tired) and nausea in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 028A21A and 006C21A) for COVID-19 immunization. No medical history reported. Concomitant products included Trintellix (vortioxetine hydrobromide) for an unknown indication. On Mar 30, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On Apr 29, 2021, received the second dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On Mar 30, 2021, patient experienced pain in extremity (sore arm), hypersomnia (slept a lot), fatigue (felt tired) and nausea. The patient treated with ibuprofen; 1 dosage form; after the first dose. On Mar 31, 2021, fatigue (felt tired) resolved. On Apr 2, 2021, pain in extremity (sore arm) resolved. At the time of the report, hypersomnia (slept a lot) and nausea outcome: unknown. Action taken with the drug in response to events: not applicable.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Severe pain in the same arm where vaccine was given; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Severe pain in the same arm where vaccine was given) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Severe pain in the same arm where vaccine was given). At the time of the report, VACCINATION SITE PAIN (Severe pain in the same arm where vaccine was given) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medicines were reported. No treatment information were reported.    This case was linked to MOD-2021-098906 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 30-Apr-2021: Follow-up was received on 30-apr-2021 and contains no new information.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Tenderness
Clinical narrative: arm is stiff, when she moves it; arm is slightly tender; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULOSKELETAL STIFFNESS (arm is stiff, when she moves it) and TENDERNESS (arm is slightly tender) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008C21A) for COVID-19 vaccination.     Concomitant products included CEFALEXIN MONOHYDRATE (KEFLEX [CEFALEXIN MONOHYDRATE]) from 27-Apr-2021 to an unknown date, CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY), LEVOTHYROXINE, PRAVASTATIN and CLOPIDOGREL BISULFATE (PLAVIX) for an unknown indication.    On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Apr-2021, the patient experienced MUSCULOSKELETAL STIFFNESS (arm is stiff, when she moves it) and TENDERNESS (arm is slightly tender). At the time of the report, MUSCULOSKELETAL STIFFNESS (arm is stiff, when she moves it) and TENDERNESS (arm is slightly tender) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Treatment information provided
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Body temperature, Body temperature abnormal, Heart rate increased
Clinical narrative: Fast heart beats; Body temperature is 100 degree; Weak; This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (Fast heart beats), BODY TEMPERATURE ABNORMAL (Body temperature is 100 degree) and ASTHENIA (Weak) in a 30-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Apr-2021, the patient experienced HEART RATE INCREASED (Fast heart beats), BODY TEMPERATURE ABNORMAL (Body temperature is 100 degree) and ASTHENIA (Weak). At the time of the report, HEART RATE INCREASED (Fast heart beats), BODY TEMPERATURE ABNORMAL (Body temperature is 100 degree) and ASTHENIA (Weak) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100 (High) 100 degree.         No concomitant medicines were reported. No treatment information were reported.  Action taken with the drug in response to events was not applicable.
Sex: F
Vaccine: COVID19
Symptoms: Product administration interrupted, Product availability issue
Clinical narrative: unable to complete her second vaccine with in the 28 day interval; unable to complete her second vaccine with in the 28 day interval; This spontaneous case was reported by a patient and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (unable to complete her second vaccine with in the 28 day interval) and PRODUCT AVAILABILITY ISSUE (unable to complete her second vaccine with in the 28 day interval) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B20A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (unable to complete her second vaccine with in the 28 day interval) and PRODUCT AVAILABILITY ISSUE (unable to complete her second vaccine with in the 28 day interval). On 29-Apr-2021, PRODUCT ADMINISTRATION INTERRUPTED (unable to complete her second vaccine with in the 28 day interval) and PRODUCT AVAILABILITY ISSUE (unable to complete her second vaccine with in the 28 day interval) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not reported.  Treatment medications was not given.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Limb discomfort, Myalgia, Pain in extremity
Clinical narrative: Temperature of 100.2; Legs hurting; Chills; Legs were little swollen; Legs hurting; Legs felt funny; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Legs were little swollen), PAIN IN EXTREMITY (Legs hurting), LIMB DISCOMFORT (Legs felt funny), PYREXIA (Temperature of 100.2) and MYALGIA (Legs hurting) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036A21A and 031A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included FAMOTIDINE (PEPCID [FAMOTIDINE]), AMLODIPINE, CARVEDILOL, CETIRIZINE HYDROCHLORIDE, SIMVASTATIN, MONTELUKAST SODIUM (SINGULAIR), SOLIFENACIN SUCCINATE (VESICARE), CALCIUM, VITAMIN D3, ESTRADIOL, LANSOPRAZOLE (PREVACID), VITAMIN C [ASCORBIC ACID] and ZINC for an unknown indication.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Apr-2021, the patient experienced PERIPHERAL SWELLING (Legs were little swollen), PAIN IN EXTREMITY (Legs hurting), LIMB DISCOMFORT (Legs felt funny), MYALGIA (Legs hurting) and CHILLS (Chills). On an unknown date, the patient experienced PYREXIA (Temperature of 100.2). The patient was treated with IBUPROFEN at an unspecified dose and frequency and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 28-Apr-2021, PERIPHERAL SWELLING (Legs were little swollen), PAIN IN EXTREMITY (Legs hurting), MYALGIA (Legs hurting) and CHILLS (Chills) had resolved. At the time of the report, LIMB DISCOMFORT (Legs felt funny) and PYREXIA (Temperature of 100.2) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Apr-2021, Body temperature: 101.2 (High) 101.2.         This case was linked to MOD-2021-091976 (Patient Link).
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling, Pyrexia
Clinical narrative: Temperature of 100.2; Legs hurting; Chills; Legs were little swollen; Legs hurting; Legs felt funny; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Legs were little swollen), PAIN IN EXTREMITY (Legs hurting), LIMB DISCOMFORT (Legs felt funny), PYREXIA (Temperature of 100.2) and MYALGIA (Legs hurting) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036A21A and 031A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included FAMOTIDINE (PEPCID [FAMOTIDINE]), AMLODIPINE, CARVEDILOL, CETIRIZINE HYDROCHLORIDE, SIMVASTATIN, MONTELUKAST SODIUM (SINGULAIR), SOLIFENACIN SUCCINATE (VESICARE), CALCIUM, VITAMIN D3, ESTRADIOL, LANSOPRAZOLE (PREVACID), VITAMIN C [ASCORBIC ACID] and ZINC for an unknown indication.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Apr-2021, the patient experienced PERIPHERAL SWELLING (Legs were little swollen), PAIN IN EXTREMITY (Legs hurting), LIMB DISCOMFORT (Legs felt funny), MYALGIA (Legs hurting) and CHILLS (Chills). On an unknown date, the patient experienced PYREXIA (Temperature of 100.2). The patient was treated with IBUPROFEN at an unspecified dose and frequency and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 28-Apr-2021, PERIPHERAL SWELLING (Legs were little swollen), PAIN IN EXTREMITY (Legs hurting), MYALGIA (Legs hurting) and CHILLS (Chills) had resolved. At the time of the report, LIMB DISCOMFORT (Legs felt funny) and PYREXIA (Temperature of 100.2) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Apr-2021, Body temperature: 101.2 (High) 101.2.         This case was linked to MOD-2021-091976 (Patient Link).
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Injection arm soreness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Injection arm soreness) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included PHENOBARBITAL (PHENOBARBITONE COX), TOPIRAMATE (TOPAMAX) and PRAVASTATIN for an unknown indication.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Mar-2021, the patient experienced VACCINATION SITE PAIN (Injection arm soreness). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (Injection arm soreness) outcome was unknown.            Treatment information was included Tylenol  Action taken with the drug in response to events was not applicable.   This case was linked to MOD-2021-098701 (E2B Linked Report).; Sender's Comments:  MOD-2021-098701:same patient, 2nd dose
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Dysphagia, Oropharyngeal discomfort
Clinical narrative: Hard to swallow; Weird sensation on the throat; This spontaneous case was reported by a consumer and describes the occurrence of DYSPHAGIA (Hard to swallow) and OROPHARYNGEAL DISCOMFORT (Weird sensation on the throat) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Apr-2021, the patient experienced DYSPHAGIA (Hard to swallow) and OROPHARYNGEAL DISCOMFORT (Weird sensation on the throat). At the time of the report, DYSPHAGIA (Hard to swallow) and OROPHARYNGEAL DISCOMFORT (Weird sensation on the throat) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medicines were reported. No treatment information were reported.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Fatigue, Feeling abnormal, Influenza like illness, Lethargy
Clinical narrative: Feeling unwell; She felt like she had flu; No energy; Felt yucky and terrible; lethargic; Felt tired; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (Feeling unwell), INFLUENZA LIKE ILLNESS (She felt like she had flu), ASTHENIA (No energy), FEELING ABNORMAL (Felt yucky and terrible) and LETHARGY (lethargic) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Osteoporosis, Lactose intolerance, Vitamin D3 deficiency and Coeliac disease. Previously administered products included for an unreported indication: FLU VACCINE VII (flu shot every year). Concurrent medical conditions included Fibromyalgia, Chronic fatigue syndrome and Allergy (pt. is allergic to at least seven antibiotics.). Concomitant products included CALCIUM CITRATE, FISH OIL, LINUM USITATISSIMUM SEED OIL (FLAX OIL), UBIDECARENONE (COQ 10), GLUCOSAMINE & CHONDORITIN, ASCORBIC ACID, COPPER GLUCONATE, TOCOPHERYL ACID SUCCINATE, XANTOFYL, ZEAXANTHIN, ZINC OXIDE (AREDS 2 VISUAL ADVANTAGE), POLYCARBOPHIL CALCIUM (FIBER), DOCUSATE SODIUM (STOOL SOFTENER) and WARFARIN for an unknown indication.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Feb-2021, the patient experienced MALAISE (Feeling unwell), INFLUENZA LIKE ILLNESS (She felt like she had flu), ASTHENIA (No energy) and FEELING ABNORMAL (Felt yucky and terrible). 17-Feb-2021, the patient experienced LETHARGY (lethargic) and FATIGUE (Felt tired). At the time of the report, MALAISE (Feeling unwell), INFLUENZA LIKE ILLNESS (She felt like she had flu), ASTHENIA (No energy), FEELING ABNORMAL (Felt yucky and terrible), LETHARGY (lethargic) and FATIGUE (Felt tired) had resolved. Not Provided          Patient got tested for Covid following first dose on 22-JAN-2021 but was negative. No concomitant medications provided. No treatment information provided.   This case was linked to MOD-2021-021025 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 30-May-2021: date of birth; other relevant history; Concomitant medication; outcome (unknown to resolved) were updated
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise
Clinical narrative: Feeling unwell; She felt like she had flu; No energy; Felt yucky and terrible; lethargic; Felt tired; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (Feeling unwell), INFLUENZA LIKE ILLNESS (She felt like she had flu), ASTHENIA (No energy), FEELING ABNORMAL (Felt yucky and terrible) and LETHARGY (lethargic) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Osteoporosis, Lactose intolerance, Vitamin D3 deficiency and Coeliac disease. Previously administered products included for an unreported indication: FLU VACCINE VII (flu shot every year). Concurrent medical conditions included Fibromyalgia, Chronic fatigue syndrome and Allergy (pt. is allergic to at least seven antibiotics.). Concomitant products included CALCIUM CITRATE, FISH OIL, LINUM USITATISSIMUM SEED OIL (FLAX OIL), UBIDECARENONE (COQ 10), GLUCOSAMINE & CHONDORITIN, ASCORBIC ACID, COPPER GLUCONATE, TOCOPHERYL ACID SUCCINATE, XANTOFYL, ZEAXANTHIN, ZINC OXIDE (AREDS 2 VISUAL ADVANTAGE), POLYCARBOPHIL CALCIUM (FIBER), DOCUSATE SODIUM (STOOL SOFTENER) and WARFARIN for an unknown indication.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Feb-2021, the patient experienced MALAISE (Feeling unwell), INFLUENZA LIKE ILLNESS (She felt like she had flu), ASTHENIA (No energy) and FEELING ABNORMAL (Felt yucky and terrible). 17-Feb-2021, the patient experienced LETHARGY (lethargic) and FATIGUE (Felt tired). At the time of the report, MALAISE (Feeling unwell), INFLUENZA LIKE ILLNESS (She felt like she had flu), ASTHENIA (No energy), FEELING ABNORMAL (Felt yucky and terrible), LETHARGY (lethargic) and FATIGUE (Felt tired) had resolved. Not Provided          Patient got tested for Covid following first dose on 22-JAN-2021 but was negative. No concomitant medications provided. No treatment information provided.   This case was linked to MOD-2021-021025 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 30-May-2021: date of birth; other relevant history; Concomitant medication; outcome (unknown to resolved) were updated
Sex: U
Vaccine: COVID19
Symptoms: Product storage error, Wrong technique in device usage process
Clinical narrative: doses were frozen and then rethawed; it was frozen, rethawed, and administered to patient; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a physician and describes the occurrence of PRODUCT STORAGE ERROR (doses were frozen and then rethawed) and WRONG TECHNIQUE IN DEVICE USAGE PROCESS (it was frozen, rethawed, and administered to patient) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016C21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT STORAGE ERROR (doses were frozen and then rethawed) and WRONG TECHNIQUE IN DEVICE USAGE PROCESS (it was frozen, rethawed, and administered to patient). At the time of the report, PRODUCT STORAGE ERROR (doses were frozen and then rethawed) and WRONG TECHNIQUE IN DEVICE USAGE PROCESS (it was frozen, rethawed, and administered to patient) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant and treatment medications were reported.
Age: 86.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Chills, Eye pain, Headache
Clinical narrative: pain over my right eye; chills; pain over her right eye, like a headache over her right eye; burning in her legs from her knees to her feet; This spontaneous case was reported by a consumer and describes the occurrence of BURNING SENSATION (burning in her legs from her knees to her feet), EYE PAIN (pain over my right eye), CHILLS (chills) and HEADACHE (pain over her right eye, like a headache over her right eye) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001B21A and 029L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 21-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced BURNING SENSATION (burning in her legs from her knees to her feet). On an unknown date, the patient experienced EYE PAIN (pain over my right eye), CHILLS (chills) and HEADACHE (pain over her right eye, like a headache over her right eye). The patient was treated with PARACETAMOL (TYLENOL) on 29-Apr-2021 for Headache, at an unspecified dose and frequency. At the time of the report, BURNING SENSATION (burning in her legs from her knees to her feet), EYE PAIN (pain over my right eye), CHILLS (chills) and HEADACHE (pain over her right eye, like a headache over her right eye) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient was reported to take Excedrin on 29-APR-2021 and Tylenol for her headache.  The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was not applicable.   This case was linked to MOD-2021-098575 (Patient Link).
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain
Clinical narrative: sore throat; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (sore throat) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Apr-2021, the patient experienced OROPHARYNGEAL PAIN (sore throat). At the time of the report, OROPHARYNGEAL PAIN (sore throat) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       For mRNA-1273 (Moderna COVID-19 Vaccine) (unknown), the reporter did not provide any causality assessments.  No concomitant and treatment medications were reported.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of vaccination site erythema (injection site was red), vaccination site pain (vaccination site tenderness) and vaccination site swelling (swollen injection site) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. The patient's past medical history included depression. Concomitant products included Lexapro (escitalopram oxalate) and bupropion for an unknown indication. On Apr 28, 2021 at 10:30 am, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On Apr 28, 2021, patient experienced vaccination site erythema (injection site was red), vaccination site pain (vaccination site tenderness) and vaccination site swelling (swollen injection site). The patient treated with ibuprofen, at an unspecified dose and frequency. At the time of the report, vaccination site erythema (injection site was red), vaccination site pain (vaccination site tenderness) and vaccination site swelling (swollen injection site) outcome: unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine): unknown. The reporter did not provide any causality assessments.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site haemorrhage
Clinical narrative: Vaccination site bleeding really bad after 1st dose,bleeding through band-aid and through shirt; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE HAEMORRHAGE (Vaccination site bleeding really bad after 1st dose,bleeding through band-aid and through shirt) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004c21a) for COVID-19 vaccination.     No medical history information was provided.  Concomitant products included LEVOTHYROXINE and GABAPENTIN for an unknown indication.    On 29-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE HAEMORRHAGE (Vaccination site bleeding really bad after 1st dose,bleeding through band-aid and through shirt). At the time of the report, VACCINATION SITE HAEMORRHAGE (Vaccination site bleeding really bad after 1st dose,bleeding through band-aid and through shirt) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       For mRNA-1273 (Moderna COVID-19 Vaccine) (unknown), the reporter did not provide any causality assessments.  No treatment medications were reported.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Allergy to vaccine, Rash
Clinical narrative: Allergic reaction; Rash around her mouth and all over the body; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of ALLERGY TO VACCINE (Allergic reaction) and RASH (Rash around her mouth and all over the body) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No relevant medical history reported.     On 26-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Apr-2021, the patient experienced ALLERGY TO VACCINE (Allergic reaction) and RASH (Rash around her mouth and all over the body). On 27-Apr-2021, ALLERGY TO VACCINE (Allergic reaction) and RASH (Rash around her mouth and all over the body) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient visited emergency room and treatment included Diphenhydramine and prednisone.  Concomitant medication was not reported.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Rash pruritic
Clinical narrative: Itchy rash; rash on my body / rash is in both arms and my chest and neck area; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of RASH PRURITIC (Itchy rash) and RASH (rash on my body / rash is in both arms and my chest and neck area) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included LISINOPRIL, ACETYLSALICYLIC ACID (ASPIRIN 81), PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] and IBUPROFEN for an unknown indication.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced RASH PRURITIC (Itchy rash) and RASH (rash on my body / rash is in both arms and my chest and neck area). The patient was treated with PREDNISONE for Adverse event, at an unspecified dose and frequency. At the time of the report, RASH PRURITIC (Itchy rash) and RASH (rash on my body / rash is in both arms and my chest and neck area) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 29-May-2021: Follow up was received on 29-MAY-2021. Events- rash and rash pruritic outcome was updated to recovered/resolved.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal discomfort, Chills, Pain
Clinical narrative: Upset stomach after 1st dose; Achy body after 1st dose; Chills after 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL DISCOMFORT (Upset stomach after 1st dose), PAIN (Achy body after 1st dose) and CHILLS (Chills after 1st dose) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 17B218 and 032B218) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concurrent medical conditions included Type 1 diabetes mellitus. Concomitant products included INSULIN GLARGINE (LANTUS), INSULIN ASPART (NOVOLOG), GABAPENTIN, LISINOPRIL and FEXOFENADINE HYDROCHLORIDE (ALLEGRA) for an unknown indication.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Mar-2021, the patient experienced ABDOMINAL DISCOMFORT (Upset stomach after 1st dose), PAIN (Achy body after 1st dose) and CHILLS (Chills after 1st dose). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, ABDOMINAL DISCOMFORT (Upset stomach after 1st dose), PAIN (Achy body after 1st dose) and CHILLS (Chills after 1st dose) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       For mRNA-1273 (Moderna COVID-19 Vaccine) (unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-098835.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Product administration interrupted, Product availability issue
Clinical narrative: Scheduled the first available appointment to get the vaccine outside the recommended timeframe; Scheduled the first available appointment to get the vaccine outside the recommended timeframe; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (Scheduled the first available appointment to get the vaccine outside the recommended timeframe) and PRODUCT AVAILABILITY ISSUE (Scheduled the first available appointment to get the vaccine outside the recommended timeframe) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (Scheduled the first available appointment to get the vaccine outside the recommended timeframe) and PRODUCT AVAILABILITY ISSUE (Scheduled the first available appointment to get the vaccine outside the recommended timeframe). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (Scheduled the first available appointment to get the vaccine outside the recommended timeframe) and PRODUCT AVAILABILITY ISSUE (Scheduled the first available appointment to get the vaccine outside the recommended timeframe) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant and treatment medications were reported.  For mRNA-1273 (Moderna COVID-19 Vaccine) (unknown), the reporter did not provide any causality assessments.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Blood count abnormal, Blood test
Clinical narrative: Changing in blood counting; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD COUNT ABNORMAL (Changing in blood counting) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029K20A) for COVID-19 vaccination.     Concurrent medical conditions included Multiple myeloma in remission (In remission more than 7 months.). Concomitant products included POMALIDOMIDE (POMALYST), DEXAMETHASONE (DEXAMETHAZONE) and DARATUMUMAB (DARZALEX) for Multiple myeloma.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced BLOOD COUNT ABNORMAL (Changing in blood counting). At the time of the report, BLOOD COUNT ABNORMAL (Changing in blood counting) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Feb-2021, Blood test: unknown (abnormal) Changing in blood counting.     mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       The patient was reported to have multiple myeloma and was in remission for more than 7 months at the time of the first vaccine dosing. She received the second dose of the Moderna vaccine on 18-FEB-2021.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.  No treatment medications were reported.   This case was linked to MOD-2021-101078 (Patient Link).
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site erythema, Vaccination site pain
Clinical narrative: Running fever for couple of days; Soreness and redness at injection site; Redness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Running fever for couple of days), VACCINATION SITE PAIN (Soreness and redness at injection site) and VACCINATION SITE ERYTHEMA (Redness at injection site) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Running fever for couple of days), VACCINATION SITE PAIN (Soreness and redness at injection site) and VACCINATION SITE ERYTHEMA (Redness at injection site). The patient was treated with PARACETAMOL (TYLENOL) for Fever, at an unspecified dose and frequency. At the time of the report, PYREXIA (Running fever for couple of days), VACCINATION SITE PAIN (Soreness and redness at injection site) and VACCINATION SITE ERYTHEMA (Redness at injection site) outcome was unknown. Not Provided          This case was linked to MOD-2021-021532 (Patient Link).
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Patient stated that she got shingle in her neck/right ear; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (Patient stated that she got shingle in her neck/right ear) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Apr-2021, the patient experienced HERPES ZOSTER (Patient stated that she got shingle in her neck/right ear). The patient was treated with ACYCLOVIR [ACICLOVIR] at a dose of 800 mg. At the time of the report, HERPES ZOSTER (Patient stated that she got shingle in her neck/right ear) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Dizziness, Fear of injection, Muscle tightness, Myalgia
Clinical narrative: afraid of getting her second dose; Severe joint pain; Nausea; Pain in back and shoulder balde; Dizziness; Felt of fainting; Tingling in the back and shoulderblades; Tightness in the back and shoulderblades; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), PRESYNCOPE (Felt of fainting), PARAESTHESIA (Tingling in the back and shoulderblades), MUSCLE TIGHTNESS (Tightness in the back and shoulderblades) and FEAR OF INJECTION (afraid of getting her second dose) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical history was provided by the reporter.     On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Apr-2021, the patient experienced DIZZINESS (Dizziness), PRESYNCOPE (Felt of fainting), PARAESTHESIA (Tingling in the back and shoulderblades), MUSCLE TIGHTNESS (Tightness in the back and shoulderblades), NAUSEA (Nausea) and MYALGIA (Pain in back and shoulder balde). On 14-Apr-2021, the patient experienced ARTHRALGIA (Severe joint pain). On an unknown date, the patient experienced FEAR OF INJECTION (afraid of getting her second dose). On 15-Apr-2021, DIZZINESS (Dizziness), PRESYNCOPE (Felt of fainting) and NAUSEA (Nausea) had resolved. On 20-Apr-2021, PARAESTHESIA (Tingling in the back and shoulderblades), MUSCLE TIGHTNESS (Tightness in the back and shoulderblades) and MYALGIA (Pain in back and shoulder balde) had resolved. At the time of the report, FEAR OF INJECTION (afraid of getting her second dose) and ARTHRALGIA (Severe joint pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were provided No Treatment information provided